<DOC>
	<DOCNO>NCT01615406</DOCNO>
	<brief_summary>This single arm , open label study 24 prostate cancer patient schedule prostatectomy and/or pelvic lymph node dissection . Patients receive single IV dose 99mTc-MIP-1404 ( study drug ) follow SPECT/CT scan 3-6 hour injection . As standard care , patient undergo prostatectomy and/or pelvic lymph node dissection ( PLND ) within two week study drug dosing . 99mTc-MIP-1404 image data evaluate visible uptake compare histopathology .</brief_summary>
	<brief_title>A Phase 1 Pilot Study 99mTc-MIP-1404 SPECT/CT Imaging Histology Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male age 21 year old . Ability provide sign informed consent willingness comply protocol requirement . Past biopsy indicate presence adenocarcinoma prostate gland . Participant deem tissue suspicious prostate cancer involvement amenable biopsy/resection . Have , undergo diagnostic CT MRI image prior surgery . Participants must agree use acceptable form birth control throughout study period . Participants must use condoms period seven day study drug administration , engage sexual activity . Participants participate would significantly delay schedule standard care therapy . Participants administer radioisotope within 5 physical half live prior study enrollment . Participants medical condition circumstance , opinion investigator , would significantly decrease obtain reliable data , achieve study objective complete study .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>